Cargando…
EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to pr...
Autores principales: | Fan, Chi-Chen, Cheng, Wei-Chung, Huang, Yu-Chuen, Sher, Yuh-Pyng, Liou, Nia-Jhen, Chien, Yu-Chuan, Lin, Pei-Shan, Lin, Pei-Syuan, Chen, Chung-Hsuan, Chang, Wei-Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668280/ https://www.ncbi.nlm.nih.gov/pubmed/29097801 http://dx.doi.org/10.1038/s41598-017-15186-y |
Ejemplares similares
-
Publisher Correction: EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
por: Fan, Chi-Chen, et al.
Publicado: (2018) -
EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis
por: Fan, Chi-Chen, et al.
Publicado: (2020) -
ICAM1 Is a Potential Cancer Stem Cell Marker of Esophageal Squamous Cell Carcinoma
por: Tsai, Sheng-Ta, et al.
Publicado: (2015) -
Structural and biochemical insights into Zn(2+)-bound EF-hand proteins, EFhd1 and EFhd2
por: Mun, Sang A, et al.
Publicado: (2023) -
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
por: Chou, Cheng-Wei, et al.
Publicado: (2019)